Risk factor
Very high price volatility
Profitability factor
Undervalued vs peers
About
Ironwood Pharmaceuticals, Inc., a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C agonist for the treatment of adults suffering from irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC) under the LINZESS name in the United States and Mexico, as well as...
Company Valuation
Considering past and projected metrics, the stock is 'cheaper' than its peers. Specifically, the stock is fairly valued on P/E, undervalued on EV/EBITDA, underpriced on P
Target Price
The average target price of IRWD is 6.3 and suggests 70% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to increas
Buy
Sell